Caleb Lee

4.3k total citations · 4 hit papers
28 papers, 1.6k citations indexed

About

Caleb Lee is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Caleb Lee has authored 28 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Public Health, Environmental and Occupational Health and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Caleb Lee's work include HER2/EGFR in Cancer Research (14 papers), Mosquito-borne diseases and control (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Caleb Lee is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Mosquito-borne diseases and control (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Caleb Lee collaborates with scholars based in United States, Japan and Singapore. Caleb Lee's co-authors include Kenji Tamura, Toshihiko Doi, Yoshihiko Fujisaki, Shanu Modi, Ian E. Krop, Javad Shahidi, Rashmi K. Murthy, Hiroji Iwata, Shunji Takahashi and Junji Tsurutani and has published in prestigious journals such as Journal of Clinical Oncology, Molecular and Cellular Biology and Cancer Research.

In The Last Decade

Caleb Lee

26 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

2020 551 citations Shanu Modi, Haeseong Park et al. Journal of Clinical Oncology profile →
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

2017 362 citations Toshihiko Doi, Kohei Shitara et al. The Lancet Oncology profile →
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

2019 258 citations Kenji Tamura, Junji Tsurutani et al. The Lancet Oncology profile →
Efficacy of Wolbachia-mediated sterility to reduce the incidence of dengue: a synthetic control study in Singapore

2024 38 citations Jue Tao Lim, Chee‐Seng Chong et al. The Lancet Microbe profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caleb Lee United States	16	1.2k	655	527	250	195	28	1.6k
Dominik Heinzmann Switzerland	14	800 0.6×	423 0.6×	108 0.2×	339 1.4×	170 0.9×	43	1.2k
Mateusz Opyrchal United States	23	1.0k 0.8×	67 0.1×	328 0.6×	272 1.1×	694 3.6×	101	1.8k
Enrico Berrino Italy	16	394 0.3×	170 0.3×	128 0.2×	271 1.1×	270 1.4×	42	849
Helen M. Moore United States	17	314 0.3×	108 0.2×	192 0.4×	452 1.8×	644 3.3×	37	1.3k
Nicolas Sirtaine Belgium	17	2.2k 1.7×	266 0.4×	484 0.9×	740 3.0×	546 2.8×	34	2.9k
Antonio Rueda Spain	21	562 0.5×	45 0.1×	177 0.3×	422 1.7×	546 2.8×	76	1.5k
Karen Dybkær Denmark	23	604 0.5×	61 0.1×	119 0.2×	393 1.6×	716 3.7×	102	1.9k
Lu Han China	19	684 0.6×	283 0.4×	137 0.3×	109 0.4×	406 2.1×	59	1.4k
Julien Racle Switzerland	17	779 0.6×	280 0.4×	437 0.8×	401 1.6×	1.4k 7.0×	26	2.1k
Emily Reisenbichler United States	13	236 0.2×	108 0.2×	95 0.2×	187 0.7×	111 0.6×	39	538

Countries citing papers authored by Caleb Lee

Since Specialization

Citations

This map shows the geographic impact of Caleb Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caleb Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caleb Lee more than expected).

Fields of papers citing papers by Caleb Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caleb Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caleb Lee. The network helps show where Caleb Lee may publish in the future.

Co-authorship network of co-authors of Caleb Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Caleb Lee. A scholar is included among the top collaborators of Caleb Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caleb Lee. Caleb Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lim, Jue Tao, Diyar Mailepessov, Chee‐Seng Chong, et al.. (2025). Adjacent spillover efficacy of Wolbachia for control of dengue: emulation of a cluster randomised target trial. BMC Medicine. 23(1). 184–184.

Lim, Jue Tao, Chee‐Seng Chong, Borame Sue Lee Dickens, et al.. (2024). Efficacy of Wolbachia-mediated sterility to reduce the incidence of dengue: a synthetic control study in Singapore. The Lancet Microbe. 5(5). e422–e432. 38 indexed citations breakdown →

Takahashi, Shunji, Hideaki Bando, Ichiro Kinoshita, et al.. (2024). Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies. Japanese Journal of Clinical Oncology. 54(4). 434–443. 6 indexed citations

Lee, Caleb, et al.. (2024). Improving drinking water quality through proficiency testing—the impact of testing method and accreditation status on Escherichia coli detection by Canadian environmental testing laboratories. Frontiers in Molecular Biosciences. 11. 1338549–1338549.

Lim, Jue Tao, Chee‐Seng Chong, Borame Sue Lee Dickens, et al.. (2024). Effectiveness of Wolbachia-mediated sterility coupled with sterile insect technique to suppress adult Aedes aegypti populations in Singapore: a synthetic control study. The Lancet Planetary Health. 8(9). e617–e628. 18 indexed citations

Lim, Jue Tao, Diyar Mailepessov, Chee‐Seng Chong, et al.. (2024). Update to: Assessing the efficacy of male Wolbachia-infected mosquito deployments to reduce dengue incidence in Singapore. Trials. 25(1). 400–400. 2 indexed citations

Jérusalem, Guy, Yeon Hee Park, Sara A. Hurvitz, et al.. (2022). Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discovery. 12(12). 2754–2762. 60 indexed citations

Im, Seock‐Ah, Binghe Xu, Sung‐Bae Kim, et al.. (2022). PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03. Annals of Oncology. 33. S464–S465. 3 indexed citations

Perez, Edith A., Chau T. Dang, Caleb Lee, et al.. (2022). Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Research and Treatment. 194(1). 1–11. 16 indexed citations

10.

Jiang, Le, et al.. (2022). Animal pose estimation: A closer look at the state-of-the-art, existing gaps and opportunities. Computer Vision and Image Understanding. 222. 103483–103483. 25 indexed citations

11.

Takahashi, Shunji, Masato Karayama, Masato Takahashi, et al.. (2021). Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. Clinical Cancer Research. 27(21). 5771–5780. 20 indexed citations

12.

Ong, Janet, et al.. (2020). Gravitrap deployment for adult Aedes aegypti surveillance and its impact on dengue cases. PLoS neglected tropical diseases. 14(8). e0008528–e0008528. 26 indexed citations

13.

Filipović, Igor, Hapuarachchige Chanditha Hapuarachchi, Caleb Lee, et al.. (2020). Using spatial genetics to quantify mosquito dispersal for control programs. BMC Biology. 18(1). 104–104. 17 indexed citations

14.

Modi, Shanu, Haeseong Park, Rashmi K. Murthy, et al.. (2020). Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study. Journal of Clinical Oncology. 38(17). 1887–1896. 551 indexed citations breakdown →

15.

Cortés, Javier, et al.. (2020). Abstract OT1-07-01: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03). Cancer Research. 80(4_Supplement). OT1–7. 3 indexed citations

16.

André, Fabrice, Javad Shahidi, Caleb Lee, Kongming Wang, & Ian E. Krop. (2020). Abstract OT1-07-04: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator’s choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02). Cancer Research. 80(4_Supplement). OT1–7. 5 indexed citations

17.

Tamura, Kenji, Junji Tsurutani, Shunji Takahashi, et al.. (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. The Lancet Oncology. 20(6). 816–826. 258 indexed citations breakdown →

18.

Doi, Toshihiko, Kohei Shitara, Yoichi Naito, et al.. (2017). Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. The Lancet Oncology. 18(11). 1512–1522. 362 indexed citations breakdown →

19.

Lee, Caleb, et al.. (2014). Performance of Canadian clinical laboratories processing throat culture proficiency testing surveys. Accreditation and Quality Assurance. 19(6). 445–450. 1 indexed citations

20.

Ahn, Jin-Woo, Todd Ashworth, Caleb Lee, et al.. (2005). Inhibition of TFII-I-Dependent Cell Cycle Regulation by p53. Molecular and Cellular Biology. 25(24). 10940–10952. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact